ArticleJournal of cannabis research2026
Electroretinographical analysis of the effect of cannabidiol (CBD) in eyes of Zucker diabetic fatty rats.
Article in Journal of cannabis research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCannabidiol (CBD), main non-psychoactive ingredient of Cannabis sativa L. is known to have anti-ischemic, antidiabetic and neuroprotective effects. Ischemia–reperfusion injury of the retina is reportedly involved in deterioration of its function in diabetic retinopathy. The study was aimed to evaluate the in vivo potential retinoprotective role of CBD in type II diabetes mellitus.
methodsZucker Diabetic Fatty (ZDF) rats were treated with CBD orally and electroretinographical analysis was carried out. In order to confirm the disease model and to assess other antidiabetic effects of CBD in ZDF rats, fasting blood glucose, oral glucose tolerance test, weight measurements and histology also took place.
resultsWeight and glucose-related analyses supported our used diabetic animal model. CBD reduced diabetic weight gain without affecting glucose levels of ZDF rats, suggesting glucose-independent mechanisms of its retinal actions. CBD treatment selectively increased dark-adapted ERG amplitudes, while leaving light-adapted responses unaffected. It did not alter reduced amplitudes and prolonged implicit times of diabetic oscillatory potentials (OPs), but lowered variability of OP amplitudes and flicker peak intervals. A potential indirect mechanism for its effects beside glutamatergic inhibition is the ability of CBD to decrease thickening of diabetic retina.
conclusionsCBD exerted glucose-independent retinoprotective effects in ZDF rats by normalizing weight gain and preventing retinal thickening. While glycemic levels were unaffected, CBD selectively enhanced rod-mediated ERG amplitudes and reduced variability indicators of OPs and flickers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.